DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

Core Points - Impact BioMedical Inc. has successfully priced its initial public offering (IPO) at $3.00 per share, with an initial offering of 1,500,000 shares, set to begin trading on the NYSE American Market on September 16, 2024 [1][2] - The IPO represents a significant milestone for DSS, enhancing shareholder value and reflecting the company's commitment to providing substantial returns to investors [2][5] - DSS previously distributed shares of Impact BioMedical to its shareholders as a stock dividend, with shareholders receiving four shares of Impact BioMedical for every one share of DSS held [3] Financial Details - The IPO is expected to close on September 17, 2024, subject to customary closing conditions [2] - Underwriters have been granted warrants to purchase up to 75,000 shares of Impact BioMedical's common stock, or 86,250 shares if the over-allotment option is fully exercised, at 125% of the IPO price per share [4] Company Background - DSS, Inc. is a multinational company with interests in various sectors, including Product Packaging, Biotechnology, and Investment Management, and has been strategically growing its portfolio through IPO spin-offs and acquisitions since 2019 [6]